Latest News

Senhwa filed an application for a patent of combination therapy of CX-4945 and CX-5461 in cancer treatment

Jul

17

2017

Senhwa CX-5461 has the potential to obtain accelerated approval for multiple indications with common biomarker

Jun

17

2017

Senhwa Biosciences Completed IPO

Apr

24

2017

Senhwa Biosciences Appoints John Soong as Chief Medical Officer

Feb

07

2017

Senhwa Biosciences CX-4945 Granted Orphan Drug Designation by the US FDA in Cholangiocarcinoma

Jan

04

2017

Senhwa CX-4945 Phase I Clinical Trial Results Accepted for Presentation at the 2017 ASCO Gastrointestinal Cancers Symposium

Dec

06

2016